阿伐考潘作为一种额外的治疗干预手段促进严重 ANCA 相关性血管炎的肾脏恢复：一例报告。
Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report.
机构信息
Department of Renal Medicine, Hervey Bay Hospital, Hervey Bay, Queensland, Australia.
Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia.
出版信息
Nephrology (Carlton). 2024 Feb;29(2):105-107. doi: 10.1111/nep.14253. Epub 2023 Nov 20.
PMID:37985226
Abstract
Avacopan, a C5a receptor antagonist (C5aR) presents a new therapeutic option to improve outcomes in ANCA-associated vasculitis (AAV). Here we present a case report of a patient initially requiring kidney replacement therapy (KRT), where avacopan was added as an additional adjunctive therapeutic agent late in the treatment course.
摘要
阿伐考潘，一种 C5a 受体拮抗剂（C5aR），为改善抗中性粒细胞胞质抗体相关性血管炎（AAV）的预后提供了一种新的治疗选择。本文报告了 1 例患者最初需要肾脏替代治疗（KRT），在治疗过程中晚期添加阿伐考潘作为附加辅助治疗药物。
Zotero 插件